- NORTH AMERICA EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Xanthic Biopharma Inc. to Commence Trading on the Canadian Securities Exchange
Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) (“Xanthic” or the “Company”) (CSE:xTHC) is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (“CSE”) under the symbol “xTHC” effective at the market open on April 19, 2018.
Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) (“Xanthic” or the “Company”) (CSE:xTHC) is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (“CSE”) under the symbol “xTHC” effective at the market open on April 19, 2018.
Tim Moore, the CEO of Xanthic, commented, “Commencing trading on the CSE is a major corporate milestone for the Xanthic team. This significant accomplishment would not have been possible without the progress made by our management team, key advisors, consultants and Board in the past year. As we enter this next phase of our corporate development, our team is excited to continue to execute our strategic vision and to provide value to our current and future shareholders.”
Further information regarding the Company is set forth in the Company’s listing statement, a copy of which is available under the Company’s SEDAR profile at www.sedar.com.
About Xanthic
Xanthic, through its wholly-owned operating subsidiary, Xanthic Biopharma Limited, provides valuable intellectual property to cannabis industry participants, enabling its strategic partners to produce high quality, innovative, non-combustible cannabis, and cannabis-infused products which deliver consistent THC and/or CBD levels. Using a proprietary process, Xanthic allows its strategic partners to deliver superior cannabinoid solubility and consistency versus competitive infused products.
Disclaimer:
This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements”). The use of any of the word “will” and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.
Click here to connect with Xanthic Biopharma Inc. (CSE:xTHC) for an Investor Presentation
Source: www.newswire.ca
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.